BIOTREE
A mass-spectrometry service company for metabolomics and proteomics, with its own metabolite standards library. It is moving into single-cell and spatial omics and pitches that data (its MetCell single-cell metabolomics in particular) as training material for virtual-cell models.
Money and evidence
No research by this company is on the record yet.
Rounds and research, on one timeline
- 2026-10-10Series BRound
nearly CNY 100M
For: multi-omics plus AI-for-Science R&D, new single-cell and spatial metabolomics and proteomics products, a multi-omics and AI mass-spectrometry capacity centre in Zhejiang, and a Singapore overseas headquarters with labs in Europe and the US
Data generationWet labManufacturing and scale-up
The company announced it through PEdaily, with its CEO and Qiming's managing partner Xubo Hu quoted; the deal lead at China Securities Capital (the private-equity arm of China Securities, not CITIC Securities) is quoted but not named. It is called the sole lead and Qiming, which solely led the 2022 Series A, is named as an existing investor continuing to invest. No valuation and no cumulative total. Founded 2012 in Shanghai per the company's own profile page, whose history section also lists four earlier rounds, from a Guozhong Ventures Pre-A to a strategic A+, that this record does not yet carry.
Lead · China Securities CapitalExisting investor · Qiming Venture Partners
On the deal: Xubo Hu (Managing Partner, Qiming Venture Partners)
Announced by the company · news.pedaily.cn ↗On the timeline →
Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.
Its investors also backed
Other companies on this page whose rounds name the same investor.
- Qiming Venture PartnersInsilico Medicine, DP Technology, Aureka Biotechnologies